Literature DB >> 33147487

A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.

Tae Gyu Oh, Susy M Kim, Cyrielle Caussy, Ting Fu, Jian Guo, Shirin Bassirian, Seema Singh, Egbert V Madamba, Ricki Bettencourt, Lisa Richards, Ruth T Yu, Annette R Atkins, Tao Huan, David A Brenner, Claude B Sirlin, Michael Downes, Ronald M Evans, Rohit Loomba.   

Abstract

Entities:  

Year:  2020        PMID： 33147487      PMCID： PMC7891106          DOI： 10.1016/j.cmet.2020.10.015

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


× No keyword cloud information.
  17 in total

1.  Microbiome signatures for cirrhosis and diabetes.

Authors:  Iain Dickson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-09       Impact factor: 46.802

Review 2.  Intestinal virome and therapeutic potential of bacteriophages in liver disease.

Authors:  Cynthia L Hsu; Yi Duan; Derrick E Fouts; Bernd Schnabl
Journal:  J Hepatol       Date:  2021-08-24       Impact factor: 25.083

3.  Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease.

Authors:  Suet-Ying Kwan; Jingjing Jiao; Aron Joon; Peng Wei; Lauren E Petty; Jennifer E Below; Carrie R Daniel; Xiaogang Wu; Jianhua Zhang; Robert R Jenq; P Andrew Futreal; Ernest T Hawk; Joseph B McCormick; Susan P Fisher-Hoch; Laura Beretta
Journal:  Hepatology       Date:  2021-12-13       Impact factor: 17.298

4.  Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection.

Authors:  Arzu Cakir; Melisa Tuncer; Hilal Taymaz-Nikerel; Ozlem Ulucan
Journal:  Pharmacogenomics J       Date:  2021-06-21       Impact factor: 3.550

Review 5.  The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk.

Authors:  Cyrielle Caussy; Adrien Aubin; Rohit Loomba
Journal:  Curr Diab Rep       Date:  2021-03-19       Impact factor: 4.810

Review 6.  Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease.

Authors:  Chathur Acharya; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2020-11-28       Impact factor: 33.883

Review 7.  Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease.

Authors:  S R Sharpton; B Schnabl; R Knight; R Loomba
Journal:  Cell Metab       Date:  2020-12-08       Impact factor: 31.373

Review 8.  Human Gut Microbiome and Liver Diseases: From Correlation to Causation.

Authors:  Rui Li; Zhengsheng Mao; Xujun Ye; Tao Zuo
Journal:  Microorganisms       Date:  2021-05-08

9.  Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl4-Induced NASH Mice and the Effect of Obeticholic Acid.

Authors:  Nanlin Zhu; Suling Huang; Qingli Zhang; Zhuohui Zhao; Hui Qu; Mengmeng Ning; Ying Leng; Jia Liu
Journal:  Metabolites       Date:  2021-06-10

10.  The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH.

Authors:  Rohit Loomba; Lei Ling; Duy M Dinh; Alex M DePaoli; Hsiao D Lieu; Stephen A Harrison; Arun J Sanyal
Journal:  Hepatology       Date:  2020-12-11       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.